Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLGA perioperative durvalumab ± tremelimumab + enfortumab vedotin in cisplatin-ineligible MIBC
jRCT2031210667Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab and enfortumab vedotin in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Event-free survival. Started Jul 2022; status: recruiting.
02
Drugs
durvalumabtremelimumabenfortumab vedotin
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on jRCT2031210667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210667.